Saturday, July 11, 2026

Drug profile · INN

nadofaragene firadenovec

nadofaragene firadenovec (ADSTILADRIN) is a interferon alpha-2 exogenous gene.

EMA: unknown Antineoplastic and immunomodulating agents (L01) L01XL10
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — nadofaragene firadenovec
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

nadofaragene firadenovec (ADSTILADRIN) is a interferon alpha-2 exogenous gene.

Key facts

INN nadofaragene firadenovec
Brand ADSTILADRIN
Mechanism Interferon alpha-2 exogenous gene
Target Interferon alpha-2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XL10

Mechanism of action

Interferon alpha-2 exogenous gene

Primary target: Interferon alpha-2

Approval history

Authority Status Date
EMA unknown

Pipeline programs

  1. 000434 Phase 3 · Ferring Pharmaceuticals · High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-mu
  2. ADSTILADRIN Phase 3 · Ferring Pharmaceuticals · Intermediate risk, non-muscle invasive bladder cancer
  3. ADSTILADRIN Phase 2 · Ferring Pharmaceuticals · Low-grade upper track urothelial carcinoma (LG-UTUC)

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is nadofaragene firadenovec?

nadofaragene firadenovec (ADSTILADRIN) is a interferon alpha-2 exogenous gene.

What is the brand name for nadofaragene firadenovec?

ADSTILADRIN is a marketed brand name for nadofaragene firadenovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.